Physician profile
William Roy Slater
NPI 1376531087
$1,254.56
in general payments reported to CMS, 2019-2025
15 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $152 · 2023: $15.33 · 2024: $53.42 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $188.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.94 | 2019-2020 | |
| Amgen INC. | $147.75 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $124.48 | 2019-2025 | Wainua |
| Pfizer INC. | $123.35 | 2025 | |
| Bridgebio Pharma, INC. | $111.67 | 2025 | Attruby |
| Amarin Pharma, INC. | $84.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $83.54 | 2019-2020 | |
| Boston Scientific Corporation | $71.54 | 2019-2020 | |
| Philips North America LLC | $40.98 | 2025 | Extended Holter |
| Sanofi-Aventis U.S. LLC | $40.64 | 2019-2020 | |
| Abbott Laboratories | $24.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.42 | 2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $22.22 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $15.33 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.